Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLASP MS cladribine study in secondary progressive multiple sclerosis
2024-516992-33-02Phase 2Authorised
- Sponsor
- Institute of Psychiatry and Neurology
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Biodribin with Placebo (2 arms). Planned start Jan 2025; status: authorised.
02
Drugs
cladribine
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2024-516992-33-02.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516992-33-02.